Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 116-121

  Takayama, Hiroki ^a   Miyake, Yasuhiro ^a   Nouso, Kazuhiro ^a   Ikeda, Fusao ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Kobashi, Haruhiko ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Fulminant hepatic failure; Hepatocyte growth factor; Platelet derived growth factor BB; Prognostic factor; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; CD31 ANTIGEN; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; VASCULOTROPIN;

ACUTE HEPATITIS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FULMINANT HEPATIC FAILURE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS;

EID: 78650311593     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06441.x     Document Type: Article

References (23)

1. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359: 558-63.
2. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G, Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol. Res. 2008; 38: 646-57.
3. Lee WM. Etiologies of acute liver failure. Semin. Liver Dis. 2008; 28: 142-52.
4. Liou IW, Larson AM. Role of liver transplantation in acute liver failure. Semin. Liver Dis. 2008; 28: 201-9.
5. Bernal W, Cross TJ, Auzinger G et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J. Hepatol. 2009; 50: 306-13.
6. Namisaki T, Yoshiji H, Kojima H et al. Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. J. Hepatol. 2006; 44: 568-75.
7. Theocharis SE, Papadimitriou LJ, Retsou ZP, Margeli AP, Ninos SS, Papadimitriou JD. Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy. Dig. Dis. Sci. 2003; 48: 1797-803.
8. Spahr L, Lambert JF, Rubbia-Brandt L et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 2008; 48: 221-9.
9. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008; 14 (Suppl 2 ): S67-79.
10. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999; 31: 929-38.
11. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J. Mol. Diagn. 2008; 10: 279-92.
12. Uto H, Ido A, Kusumoto K et al. Development of a rapid semi-quantitative immunochromatographic assay for serum hepatocyte growth factor and its usefulness in acute liver failure. Hepatol. Res. 2005; 33: 272-6.
13. Miura N, Kabashima H, Shimizu M et al. Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis. Hepatol. Int. 2008; 2: 213-21.
14. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003; 9: 653-60.
15. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008; 16: 585-601.
16. Okumoto K, Saito T, Onodera M et al. Serum levels of stem cell factor and thrombopoietin are markedly decreased in fulminant hepatic failure patients with a poor prognosis. J. Gastroenterol. Hepatol. 2007; 22: 1265-70.
17. Afdhal N, McHutchison J, Brown R et al. Thrombocytopenia associated with chronic liver disease. J. Hepatol. 2008; 48: 1000-7.
18. Assy N, Spira G, Paizi M et al. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J. Hepatol. 1999; 30: 911-15.
19. Antoine M, Tag CG, Wirz W et al. Upregulation of pleiotrophin expression in rat hepatic stellate cells by PDGF and hypoxia: implications for its role in experimental biliary liver fibrogenesis. Biochem. Biophys. Res. Commun. 2005; 337: 1153-64.
20. Hendel RC, Henry TD, Rocha-Singh K et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000; 101: 118-21.
21. Hedman M, Hartikainen J, Syvänne M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-83.
22. Ido A, Moriuchi A, Marusawa H et al. Translational research on HGF: a phase I/II study of recombinant human HGF for the treatment of fulminant hepatic failure. Hepatol. Res. 2008; 38: S88-S92.
23. Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. Ther. Apher. 2002; 6: 419-24.